• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

June 7, 2023

One-Third of Adults With Type 2 Diabetes May Have Undetected, Symptomless Cardiovascular Disease

Author(s):

Erin Hunter, Assistant Editor

Levels of troponin were higher in people who had type 2 diabetes for a longer period than people with healthy blood levels.

Elevated levels of protein biomarkers were associated with undetected and symptomless cardiovascular (CV) disease (CVD) in one-third of adults with type 2 diabetes (T2D) compared to those without, according to research published in the Journal of the American Heart Association. Screening for cardiac biomarkers could be added to routine assessment evaluating cardiovascular (CV) risk factors to create preventative strategies, according to the study authors.

Doctor checking blood sugar level with glucometer. Credit: Proxima Studio - stock.adobe.com

Credit: Proxima Studio - stock.adobe.com

“What we are seeing is that many people with type 2 diabetes who have not had a heart attack, or a history of CVD are at high risk for CV complications,” said study co-author Elizabeth Selvin, PhD, MPh, a professor of epidemiology at Johns Hopkins Bloomberg School of Public Health in Baltimore, in the press release. “These cardiac biomarkers give us a window into CV risk in people who otherwise might not be recognized as highest risk.”

In 2020, the AHA estimated that 102,188 deaths were attributed to diabetes. T2D is linked to traditional risk factors of cardiac health, including high blood pressure (BP) and cholesterol. However, cholesterol and high BP are not the only factors that influence heart health in patients with T2D, Selvin explained. In these instances, “cholesterol-lowering medications are not going to prevent cardiac damage,” she said.

Investigators believe that other biomarkers could identify risk of CVD, including troponin T and N-terminal pro-B-type natriuretic peptide. These are cardiac protein biomarkers that measure injury and stress to the heart and help diagnose heart attack and heart failure. But when these blood proteins levels are only slightly elevated, they could also serve as early warning signs of risk of future heart failure, coronary heart disease, or death.

In the current study, investigators looked at 10,300 blood samples of adults with and without T2D that were collected from the US National Health and Nutrition Examination Survey (1999 to 2004). They studied the association between the 2 protein biomarkers and risk of CV death or all-cause mortality and used them to identify previously unrecognized and symptomless CVD.

The results showed that adults with T2D had more than double the occurrence of undetected CVD compared to those without diabetes (33.4% and 16.1%). Adjusting for other CV risk factors, adults with T2D also had higher troponin and Nterminal pro-B-type natriuretic peptide levels in the blood, which are associated with a 77% and 78% increased risk of all-cause death, respectively.

The team also observed that T2D was associated with elevated levels of troponin, despite age, sex, race/ethnicity, and weight. N-terminal pro-B-type natriuretic peptide levels were not higher in people with T2D and adjusting for age. Although the study found an association between the protein biomarkers and risk of CVD, it did not identify heart disease, heart failure, stroke event, or CV complication as biomarkers of CV complications, therefore more research is needed.

“Measuring biomarkers more routinely may help us focus on CV prevention therapies for people with type 2 diabetes who are at higher risk,” Selvin said in the press release.

Reference

American Heart Association. 1 in 3 adults with Type 2 diabetes may have undetected cardiovascular disease. News Release. May 31, 2023. Accessed on May 31, 2023. https://www.eurekalert.org/news-releases/990479

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Related Content
Advertisement
Skincare foam -- Image credit: Pavel | stock.adobe.com
Published: May 22nd 2025 | Updated: May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Doctor with human Eye anatomy model with magnifying glass. Eye disease, Refractive Errors, Age Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, Amblyopia, Strabismus and Healt - Image credit: Jo Panuwat D | stock.adobe.com
May 22nd 2025

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Adalimumab Medical Injection - Image credit: luchschenF | stock.adobe.com
May 22nd 2025

FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses

Kennedy Ferruggia, Assistant Editor
3D visualization of natural killer cells | Image Credit: © N0X - stock.adobe.com
May 22nd 2025

Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Skincare foam -- Image credit: Pavel | stock.adobe.com
Published: May 22nd 2025 | Updated: May 22nd 2025

FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis in Adults and Children

Gillian McGovern, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Doctor with human Eye anatomy model with magnifying glass. Eye disease, Refractive Errors, Age Related Macular Degeneration, Cataract, Diabetic Retinopathy, Glaucoma, Amblyopia, Strabismus and Healt - Image credit: Jo Panuwat D | stock.adobe.com
May 22nd 2025

FDA Approves Ranibizumab Injection for Treatment of Diabetic Retinopathy

Kennedy Ferruggia, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Adalimumab Medical Injection - Image credit: luchschenF | stock.adobe.com
May 22nd 2025

FDA Grants Interchangeability Designation to Yuflyma, Biosimilar for Humira Across All Approved Doses

Kennedy Ferruggia, Assistant Editor
3D visualization of natural killer cells | Image Credit: © N0X - stock.adobe.com
May 22nd 2025

Distinct NK Cell Subset Predicts Ibrutinib Response and Immune Pathway Activation in CLL

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.